As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Researchers sought to determine whether extramedullary lesions would be an indicator of prognosis in patients with multiple myeloma treated in the first line with bortezomib.
A systematic review identified nursing tips for the care of pediatric patients at risk of cytokine release syndrome after blinatumomab or CAR-T therapy.
